SUVRETTA CAPITAL MANAGEMENT, LLC 13D and 13G filings for Spyre Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:28 pm Purchase |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
SUVRETTA CAPITAL MANAGEMENT, LLC | 412,395 1.000% |
412,395 (New Position) |
Filing |